3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
pembrolizumab
247
Nivolumab
144
Cyclophosphamide
137
Cisplatin
137
Paclitaxel
115
Carboplatin
111
Gemcitabine
100
Radiotherapy
86
Dexamethasone
84
Docetaxel
79
Ipilimumab
70
atezolizumab
68
Doxorubicin
63
Fluorouracil
60
Blood Specimen Collection
60
Bevacizumab
59
Etoposide
55
fludarabine
54
Rituximab
54
Oxaliplatin
52
Prednisone
51
Lenalidomide
51
Surveys and Questionnaires
50
Cetuximab
47
Standard of Care
46
Capecitabine
46
Radiosurgery
44
Magnetic Resonance Spectroscopy
44
lenvatinib
43
durvalumab
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
1 year
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled